Delayed Action

This month, Jeffrey Bouley takes a look at some of the potential issues that could provide complications for the disbursement of funds by the California Institute for Regenerative Medicine (CIRM), the body created with the passage of Proposition 71 in 2004 which provided $3 billion in state funds for embryonic stem cell research (see editconnect E050605). Apparently some folks have been stirring the pot of foment by questioning both the potential royalties schedule faced by researchers
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00
This month, Jeffrey Bouley takes a look at some of the potential issues that could provide complications for the disbursement of funds by the California Institute for Regenerative Medicine (CIRM), the body created with the passage of Proposition 71 in 2004 which provided $3 billion in state funds for embryonic stem cell research (see editconnect E050605).
Apparently some folks have been stirring the pot of foment by questioning both the potential royalties schedule faced by researchers getting funds from CIRM as well as potential roadblocks faced due to broad embryonic stem cell patents held by the Wisconsin Alumni Research Foundation (WARF).

For its part, WARF says not to worry, that it has been typically generous in providing free licenses to folks engaged in embryonic stem cell research. There really is no reason to expect otherwise and frankly, I'm guessing the folks at CIRM would love to have this kind of problem right now. It would at least mean that they had begun dispersing large chunks of the roughly $300 million in grants it expects to average every year over the next ten years.
Continue reading below...
Illustration of diverse healthcare professionals interacting with digital medical data and health records on virtual screens.
WebinarsAccelerating rare disease clinical trials
Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.
Read More

Unfortunately, some 18 months after nearly 60 percent of California voters approved the measure, CIRM has only provided roughly $14 million in grants to stem cell researchers. No, this is not the classic case of a new bureaucracy stumbling to get organized. Rather it is the result of numerous lawsuits—the last resort of the disgruntled who find themselves on the short end of the stick after a vote.

Allies in this litigation are The California Family Bioethics Council, a conservative Christian advocacy group and the taxpayer group Peoples Ad-vocate. Both have questioned the constitutionality of CIRM based essentially on its structure—though we can all guess the real reasons each would prefer to find a legal victory after a crushing defeat at the ballot box.

So far, CIRM has prevailed on the legal challenges, the most recent an April 21 decision by Alameda County Judge Bonnie Sabraw that said the lawsuits failed to show that the law created by Proposition 71 "was clearly, positively and unmistakably unconstitutional."
Continue reading below...
A scientist wearing gloves handles a pipette over a petri dish and a color-coded microplate in a laboratory setting.
Application NoteThe unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Read More

Certainly, this was good news for the folks at CIRM and the majority of voters in the Golden State, but it isn't expected to be the last court ruling needed to allow the state to finally begin selling the bonds to fund the research. In fact, if this issue ends up in the California Supreme Court, which seems inevitable, it could be another year before the legal questions—such as they are —are settled.

Unfortunately, this is not a one-front battle for CIRM. Concurrent with the legal actions has been a concerted effort by some state legislators to pass laws that would make the oversight, documentation and procedures necessary to grant money, costly and time consuming.

In other words, the strategy for those who oppose the effort is one of delaying for as long as possible any research or to at least limit the dollars available to scientists by forcing CIRM to eat up much of its funds in administrative costs.
Continue reading below...
A 3D rendering of round clear cells with multiple red round nodules in each cellular center representing nuclei, suspended in a liquid, clear backdrop.
WhitepaperAutomating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
Read More

The frustration among public officials in California these days is palpable, the legal challenges alone prompted California Attorney General Bill Lockyer to comment: "It's unfortunate that the plaintiffs, after losing at the polls, went to court to frustrate the voters' will."

The sad thing is it never should have come to this. Current, wrong-headed, federal guidelines for public funding of embryonic stem cell medical research created this mess. California was merely trying to provide some measure of "progressive" public financing for what is important—dare I say, necessary—research.

Public opinion is also on the side of embryonic stem cell research, again nearly 60 percent of all Americans in favor, while the numbers of those opposed continues to shrink well south of 20 percent.
It is well past time for this very vocal minority to simply do what you sometimes need to do in a democracy: drop the zealotry and accept the will of the majority.
Continue reading below...
An image of a western blot transfer showing the white, square transfer membrane with orange and blue bands representing the protein molecules undergoing transfer on a black and white machine.
CompendiumExploring stain-free western blotting
Researchers can achieve seamless western blot experiments by implementing advancements in stain-free technology, normalization methods, and compliance integration.
Read More

And let the scientists get to work.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Portrait of Scott Weitze, Vice President of Research and Technical Standards at My Green Lab, beside text that reads “Tell us what you know: Bringing sustainability into scientific research,” with the My Green Lab logo.
Laboratories account for a surprising share of global emissions and plastic waste, making sustainability a priority for modern research.
3D illustration of RNA molecules on a gradient blue background.
With diverse emerging modalities and innovative delivery strategies, RNA therapeutics are tackling complex diseases and unmet medical needs.
A 3D rendering of red and yellow protein molecules floating in a fluid-like environment.
Discover approaches that shorten the path from DNA constructs to purified, functional proteins.
Drug Discovery News September 2025 Issue
Latest IssueVolume 21 • Issue 3 • September 2025

September 2025

September 2025 Issue

Explore this issue